Literature DB >> 27189494

Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.

Leon Chen1, Sirunya Silapunt1, Michael R Migden1,2.   

Abstract

The Hedgehog inhibitors are promising alternative for patients with advanced basal cell carcinoma that are not amenable to radiotherapy or surgery. Sonidegib, also known as LDE225, is an orally available SMO antagonist that was recently approved by the US FDA for the treatment of patients with locally advanced basal cell carcinoma. This article will provide an overview of the pharmacology and pharmacokinetics of sonidegib and in-depth analysis of the BOLT trial with additional data from the 12-month update. The present challenges associated with Hedgehog inhibitors will also be discussed.

Entities:  

Keywords:  BOLT trial; basal cell carcinoma; sonidegib

Mesh：

Substances：

Year:  2016        PMID： 27189494     DOI： 10.2217/fon-2016-0118

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  7 in total

Review 1.  Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma.

Authors:  Mohd Wahid; Arshad Jawed; Sajad Ahmad Dar; Raju K Mandal; Shafiul Haque
Journal:  Onco Targets Ther       Date:  2017-01-24       Impact factor: 4.147

Review 2.  Emerging concepts and recent advances in basal cell carcinoma.

Authors:  Mariam Totonchy; David Leffell
Journal:  F1000Res       Date:  2017-12-04

Review 3.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

Review 4.  Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma.

Authors:  Jia Ding; Hui-Yan Li; Li Zhang; Yuan Zhou; Jian Wu
Journal:  Cells       Date:  2021-01-11       Impact factor: 6.600

Review 5.  New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.

Authors:  Alessia Villani; Luca Potestio; Gabriella Fabbrocini; Massimiliano Scalvenzi
Journal:  Adv Ther       Date:  2022-01-28       Impact factor: 3.845

6.  Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligand.

Authors:  Xianjun Zhang; Fei Zhao; Yiran Wu; Jun Yang; Gye Won Han; Suwen Zhao; Andrii Ishchenko; Lintao Ye; Xi Lin; Kang Ding; Venkatasubramanian Dharmarajan; Patrick R Griffin; Cornelius Gati; Garrett Nelson; Mark S Hunter; Michael A Hanson; Vadim Cherezov; Raymond C Stevens; Wenfu Tan; Houchao Tao; Fei Xu
Journal:  Nat Commun       Date:  2017-05-17       Impact factor: 14.919

Review 7.  Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma.

Authors:  Alessia Villani; Gabriella Fabbrocini; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.